Insmed Inc. Terminates Material Definitive Agreement

Ticker: INSM · Form: 8-K · Filed: 2024-11-19T00:00:00.000Z

Sentiment: neutral

Topics: agreement-termination, material-event

Related Tickers: INSM

TL;DR

INSMED terminated a big deal, could affect future plans.

AI Summary

Insmed Incorporated announced on November 18, 2024, the termination of a material definitive agreement. The company, incorporated in Virginia with its principal executive offices in Bridgewater, New Jersey, filed this 8-K report to disclose this event.

Why It Matters

The termination of a material definitive agreement can significantly impact a company's financial standing, strategic partnerships, and future operations.

Risk Assessment

Risk Level: medium — Termination of a material definitive agreement often signals potential disruptions or changes in business strategy, which can introduce uncertainty.

Key Players & Entities

FAQ

What specific material definitive agreement was terminated by Insmed Incorporated?

The filing does not specify the exact name or details of the material definitive agreement that was terminated.

When did the termination of the material definitive agreement become effective?

The filing indicates that the earliest event reported related to this termination occurred on November 18, 2024.

What is the primary reason for the termination of this agreement?

The provided text does not disclose the reason for the termination of the material definitive agreement.

Does this termination have any immediate financial implications for Insmed?

The filing does not detail any immediate financial implications resulting from the termination.

Are there any other companies involved in this terminated agreement?

The filing does not mention any other specific companies involved in the terminated agreement.

Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-11-19 08:00:29

Key Financial Figures

Filing Documents

02 – Termination of a Material Definitive Agreement

ITEM 1.02 – Termination of a Material Definitive Agreement. As previously disclosed, on February 22, 2024, Insmed Incorporated (the "Company") entered into a Sales Agreement (the "Agreement") with Leerink Partners LLC, as agent ("Leerink"), under which the Company may offer and sell its common stock, par value $0.01 per share, from time to time having an aggregate offering price of up to $500,000,000 during the term of the Agreement through Leerink, acting as agent. On November 18, 2024, the Company terminated the Agreement, which termination was immediately effective. Since September 30, 2024, no shares of common stock have been issued or sold pursuant to the Agreement. The Company is not subject to any termination penalties related to the termination of the Agreement. A copy of the Agreement was filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on February 22, 2024 (the "Prior Form 8-K"). The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit 10.1 to the Prior Form 8-K.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 19, 2024 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary

View on Read The Filing